Search Results

PurMinds NeuroPharma to initiate preclinical development of lead candidate PUR501 in 2024 in preparation for IND submission

PurMinds NeuroPharma (“PurMinds™" or the “Company”), a clinical-stage neuroscience company focused on advancing a robust pipeline of small molecules, psychedelic compounds, and other modalities for the treatment of neurological and neurodegenerative disorders

Impel NeuroPharma announced that Adrian Adams, Chairman and Chief Executive Officer, will participate in the following upcoming investor conferences.

Impel NeuroPharma announced that Chairman of the Board and Chief Executive Officer, Adrian Adams will ring the Nasdaq Stock Market closing bell on Monday, April 25, 2022.

PurMinds NeuroPharma (“PurMinds” or the “Company”), a neuro-medicine development company focused on advancing novel therapeutics for neurological and neurodegenerative disorders, today announced that it has signed the first Controlled Substances Supply Agreement with Bluestem API Inc (“Bluestem”) to produce and supply botanical psilocybin from its Ontario based neurolab and production facility that holds a Dealer’s License for Controlled Drugs and Substances (“DL”).

Impel NeuroPharma announced two separate transactions with funds managed by Oaktree Capital Management, L.P. totaling $100 million in gross funding.

PurMinds NeuroPharma Inc. (“PurMinds™" or the “Company”), a clinical-stage neuroscience company dedicated to the development of innovative therapies for neurological and neurodegenerative disorders

Impel NeuroPharma announced that Adrian Adams, Chairman and Chief Executive Officer, will present a company overview at the 21st Annual Needham Healthcare Conference being held virtually on Thursday, April 14, 2022 at 1:30 p.m. ET.

Impel NeuroPharma today provided updates on Trudhesa™ (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) launch progress and recent business highlights.

Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced planned poster presentations at the upcoming American Academy of Neurology (AAN) annual meeting.